PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)

NCT06074692 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Sarcoma
Sarcoma,Soft Tissue
Sarcoma of Bone

Interventions

COMBINATION_PRODUCT: Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)

Sponsor

Ruijin Hospital